![Biomedicines | Free Full-Text | Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis | HTML Biomedicines | Free Full-Text | Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis | HTML](https://www.mdpi.com/biomedicines/biomedicines-09-01111/article_deploy/html/images/biomedicines-09-01111-g002.png)
Biomedicines | Free Full-Text | Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis | HTML
![Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial - The Lancet Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a7fecd72-8d29-4960-b104-0b092234797c/gr1_lrg.gif)
Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial - The Lancet
![Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer - Journal of Hepatology Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ac991feb-f289-4156-ad73-370d2953ad94/fx1_lrg.jpg)
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer - Journal of Hepatology
![Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial | Breast Cancer Research | Full Text Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01415-w/MediaObjects/13058_2021_1415_Fig1_HTML.png)
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial | Breast Cancer Research | Full Text
![Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) - ScienceDirect Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842820301165-gr2.jpg)
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB) - ScienceDirect
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/44899b13-721b-49c0-acd7-ab9c0276b0ac/gr1_lrg.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial | Breast Cancer Research | Full Text Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01415-w/MediaObjects/13058_2021_1415_Fig4_HTML.png)